Role of CD147 in Acute Myeloid Leukemia
Yasmine Abd El-Rahman Naguib Ibrahim;
Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that arise in precursors of myeloid, erythroid, megakaryocytic and monocytic cell lineages from clonal transformation of hematopoietic precursors and block in differentiation of hematopoiesis, resulting in growth of a clonal population of neoplastic cells or blasts that interfere with the production of normal blood cells and leads to fatal infection, bleeding, or organ infiltration in the absence of treatment within one year of diagnosis.
AML has the lowest survival rate of all leukemias.So, assessment of the prognostic factors in AML is very important. Additional markers with prognostic significance are needed to identify clinical characteristics of AML patients for a better prognostic evaluation and a more appropriate therapeutic approach.
This present study aimed to assess CD147 expression in adult patients with denovo AML and to correlate its expression with standard prognostic factors.
The current study was carried out on 50 newly diagnosed AML patients. All patients were subjected to complete history taking, thorough clinical examination and laboratory investigations including: complete blood picture, bone marrow aspiration with examination of Leishman-stained peripheral blood and bone marrow smears, immunophenotyping and detection of the level of CD147 expression by flow cytometry. The CD147 was expressed in all studied AML patients, but without a significant difference than control group in percentage elevation or MFI.
There was no significant association between CD147 expression with any of the studied demographic, clinical or laboratory variables, response to chemotherapy or disease outcome. Moreover, CD147 percentage expression showed no significant relation with cytogenetic analysis. However, a significant relation betweenhigher levels of CD147 MFI and unfavorable karyotype in AML patients was found.
Finally, the results of the present study proved that although CD147 was elevated in AML, it can’t be considered an independent prognostic factor.
AML has the lowest survival rate of all leukemias.So, assessment of the prognostic factors in AML is very important. Additional markers with prognostic significance are needed to identify clinical characteristics of AML patients for a better prognostic evaluation and a more appropriate therapeutic approach.
This present study aimed to assess CD147 expression in adult patients with denovo AML and to correlate its expression with standard prognostic factors.
The current study was carried out on 50 newly diagnosed AML patients. All patients were subjected to complete history taking, thorough clinical examination and laboratory investigations including: complete blood picture, bone marrow aspiration with examination of Leishman-stained peripheral blood and bone marrow smears, immunophenotyping and detection of the level of CD147 expression by flow cytometry. The CD147 was expressed in all studied AML patients, but without a significant difference than control group in percentage elevation or MFI.
There was no significant association between CD147 expression with any of the studied demographic, clinical or laboratory variables, response to chemotherapy or disease outcome. Moreover, CD147 percentage expression showed no significant relation with cytogenetic analysis. However, a significant relation betweenhigher levels of CD147 MFI and unfavorable karyotype in AML patients was found.
Finally, the results of the present study proved that although CD147 was elevated in AML, it can’t be considered an independent prognostic factor.
Other data
| Title | Role of CD147 in Acute Myeloid Leukemia | Other Titles | دور بروتين CD147فى حالات سرطان الدم النقــوى الحــاد | Authors | Yasmine Abd El-Rahman Naguib Ibrahim | Issue Date | 2014 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.